<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Cancer" post="CellCancer CellCancer Cell1535-61081878-3686Cell Press S1535-6108(20)30257-9 doi: 10.1016/j.ccell.2020.05.007 : Article"/>
 <result pre="Press S1535-6108(20)30257-9 doi: 10.1016/j.ccell.2020.05.007 : Article NCIâ€™s Work to Advance" exact="Cancer" post="Research while Responding to the COVID-19 Pandemic SingerDinah S.singerd@mail.nih.gov1âˆ—[1],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="centre remains active. Abstract During the COVID-19 pandemic, the National" exact="Cancer" post="Institute (NCI) is bringing to bear its considerable expertise"/>
 <result pre="responding to the pandemic, NCIâ€™s priority remains the advancement of" exact="cancer" post="research. NCI has implemented many flexibilities for grantees and"/>
 <result pre="for grantees and trainees. During the COVID-19 pandemic, the National" exact="Cancer" post="Institute (NCI) is bringing to bear its considerable expertise"/>
 <result pre="responding to the pandemic, NCIâ€™s priority remains the advancement of" exact="cancer" post="research. NCI has implemented many flexibilities for grantees and"/>
 <result pre="the worldwide effort to better understand and mitigate COVID-19. However," exact="cancer" post="has not come to a halt during this period,"/>
 <result pre="the needs of people with cancer. As the worldâ€™s largest" exact="cancer" post="research organization, we remain committed to sustaining progress against"/>
 <result pre="NCIâ€™s number one priority is, and always will be, advancing" exact="cancer" post="research and reducing the burden of cancer. Frederick National"/>
 <result pre="and reducing the burden of cancer. Frederick National Laboratory for" exact="Cancer" post="Research Central to SARS-CoV-2 Research In particular, we have"/>
 <result pre="the burden of cancer. Frederick National Laboratory for Cancer Research" exact="Central" post="to SARS-CoV-2 Research In particular, we have pivoted some"/>
 <result pre="the capacities and resources of the Frederick National Laboratory for" exact="Cancer" post="Research (FNLCR), which houses cutting-edge technologies and research resources"/>
 <result pre="that are directly relevant and tailor-made to respond to this" exact="viral" post="pandemic. FNLCR scientists have worked on earlier virus epidemics,"/>
 <result pre="collaboration with experts from the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID). FNLCR recently worked closely with NIAID, the"/>
 <result pre="with experts from the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID). FNLCR recently worked closely with NIAID, the Centers"/>
 <result pre="(NIAID). FNLCR recently worked closely with NIAID, the Centers for" exact="Disease" post="Control and Prevention (CDC), and several academic medical centers"/>
 <result pre="FNLCR to identify genetic variants associated with outcomes in both" exact="cancer" post="and non-cancer patients with COVID-19. The goal is to"/>
 <result pre="to expedite progress in understanding, treating, and preventing the deadly" exact="viral" post="disease. Many scientists and clinicians within NCIâ€™s large networks"/>
 <result pre="in conducting complex clinical trials and are temporarily pivoting some" exact="cancer" post="research activities, including clinical trials, epidemiological studies, and basic"/>
 <result pre="response, is one of the potentially fatal adverse effects of" exact="cancer" post="immunotherapies that NCI researchers are familiar with and are"/>
 <result pre="NCI quickly launched the trial and is conducting it with" exact="adult" post="and pediatric patients affected by cancer and COVID-19 who"/>
 <result pre="is conducting it with adult and pediatric patients affected by" exact="cancer" post="and COVID-19 who have severe respiratory complications thought to"/>
 <result pre="pediatric patients affected by cancer and COVID-19 who have severe" exact="respiratory" post="complications thought to be caused by cytokine storm. The"/>
 <result pre="of the drug. NCI is initiating a longitudinal cohort of" exact="cancer" post="patients infected with SARS-CoV-2, called NCI COVID-19 in Cancer"/>
 <result pre="of cancer patients infected with SARS-CoV-2, called NCI COVID-19 in" exact="Cancer" post="Patients Study (NCCaPS). Working through the NCI clinical trials"/>
 <result pre="(NCCaPS). Working through the NCI clinical trials networks and NCI-designated" exact="cancer" post="centers, our target is to enroll more than 2,000"/>
 <result pre="ages with the goal of generating a comprehensive dataset of" exact="cancer" post="types, treatments, medications, symptoms, and outcomes. The study will"/>
 <result pre="course of the virus in people with cancer. Many NCI-designated" exact="cancer" post="centers, on their own or in collaboration with other"/>
 <result pre="cancer centers, on their own or in collaboration with other" exact="cancer" post="centers, have also moved rapidly to launch novel therapeutic"/>
 <result pre="also moved rapidly to launch novel therapeutic clinical trials involving" exact="cancer" post="patients with COVID-19. One example is the COVID-19 and"/>
 <result pre="cancer patients with COVID-19. One example is the COVID-19 and" exact="Cancer" post="Consortium led by the Vanderbilt-Ingram Cancer Center. Because cancer"/>
 <result pre="is the COVID-19 and Cancer Consortium led by the Vanderbilt-Ingram" exact="Cancer" post="Center. Because cancer patients may be at increased risk"/>
 <result pre="and Cancer Consortium led by the Vanderbilt-Ingram Cancer Center. Because" exact="cancer" post="patients may be at increased risk of developing complications"/>
 <result pre="SARS-CoV-2, Vanderbilt has galvanized a group of more than 80" exact="cancer" post="centers and other organizations that are collecting clinical data"/>
 <result pre="centers and other organizations that are collecting clinical data on" exact="cancer" post="patients who have been infected with COVID-19. The intent"/>
 <result pre="being conducted in the context of NCI-funded work is the" exact="Cancer" post="Moonshot-funded Cellular Immunotherapy Data Resource (CIDR) program, which collects"/>
 <result pre="CIDR has expanded its focus to collect data on COVID-19" exact="infections" post="and deaths among patients receiving cellular therapy. Impact of"/>
 <result pre="deaths among patients receiving cellular therapy. Impact of COVID-19 on" exact="Cancer" post="Research Although NCI is responding to the COVID-19 crisis,"/>
 <result pre="to the COVID-19 crisis, NCIâ€™s mission, first and foremost, is" exact="cancer" post="research and care. NCI is taking steps to help"/>
 <result pre="care. NCI is taking steps to help keep the nationâ€™s" exact="cancer" post="research enterprise operating to the fullest extent possible. Nonetheless,"/>
 <result pre="the COVID-19 pandemic has caused an unprecedented disruption throughout the" exact="cancer" post="research community, slowed down cancer clinical trial operations, and"/>
 <result pre="an unprecedented disruption throughout the cancer research community, slowed down" exact="cancer" post="clinical trial operations, and limited the healthcare systemâ€™s resources."/>
 <result pre="cancer research community, slowed down cancer clinical trial operations, and" exact="limited" post="the healthcare systemâ€™s resources. It has indeed become a"/>
 <result pre="It has indeed become a delicate balancing act to advance" exact="cancer" post="science while keeping cancer patients, many of whom are"/>
 <result pre="a delicate balancing act to advance cancer science while keeping" exact="cancer" post="patients, many of whom are immunosuppressed, and staff safe"/>
 <result pre="accrual has sharply declined, NCI is working to ensure that" exact="cancer" post="center trials offering potentially life-saving therapies and trials where"/>
 <result pre="distancing. NCI will exercise all available options to support the" exact="cancer" post="research community throughout this difficult period. We understand that"/>
 <result pre="research community throughout this difficult period. We understand that many" exact="cancer" post="scientists may want to temporarily focus their attention on"/>
 <result pre="for redirecting current grant resources to COVID-19-related projects that are" exact="cancer" post="relevant and can be initiated immediately (Box 1 )."/>
 <result pre="Funding Opportunities Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus" exact="Disease" post="2019 (COVID-19): NOT-CA-20-043 Availability of Urgent Competitive Revision and"/>
 <result pre="Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus" exact="Disease" post="2019 (COVID-19): NOT-CA-20-042 Participation in PA-18-935 â€œUrgent Competitive Revision"/>
 <result pre="aware that the research community is experiencing considerable stress and" exact="anxiety" post="about the consequences of COVID-19 on their research grants"/>
 <result pre="their research grants and careers. NCI is committed to keeping" exact="cancer" post="research moving forward. New policies have been implemented during"/>
 <result pre="investigators and trainees. This flexibility will help sustain progress in" exact="cancer" post="research and permit normal activities to resume to their"/>
 <result pre="unique implementation science opportunity. We are already seeing that many" exact="cancer" post="patients find telehealth more convenient for some aspects of"/>
 <result pre="has disrupted life around the world, and that includes the" exact="cancer" post="research enterprise. The novel virus continues to challenge us"/>
 <result pre="return to normal, albeit a different normal. This disruption in" exact="cancer" post="research should be viewed as only a temporary pause."/>
 <result pre="fact has and always will remain permanentâ€&quot;NCIâ€™s commitment to advancing" exact="cancer" post="research and care."/>
</results>
